Arcosa Inc
Change company Symbol lookup
Select an option...
ACA Arcosa Inc
ENBL Enable Midstream Partners LP
SPVU Invesco S&P 500® Enhanced Value ETF
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
SPG Simon Property Group Inc
SPFF Global X SuperIncome™ Preferred ETF
SPDV AAM S&P 500 High Dividend Value ETF
SOXS Direxion Daily Semiconductor Bear 3X Shares
SOXL Direxion Daily Semiconductor Bull 3X Shares
SOLOW Electrameccanica Vehicles Corp *W EXP 08/13/2023
Go

Industrials : Construction & Engineering | Small Cap Blend
Company profile

Arcosa, Inc. is focused on manufacturing and producing infrastructure-related products and services. The Company provides its products to a spectrum of markets throughout construction, energy, and transportation. The Company operates through three segments: Construction Products Group, Energy Equipment Group, and Transportation Products Group. The Construction Products Group segment produces and sells construction aggregates and manufactures and sells trench shields and shoring products and services for infrastructure-related projects. The Energy Equipment Group segment manufactures and sells products for energy-related businesses, including structural wind towers, steel utility structures for electricity transmission and distribution, and storage and distribution containers. The Transportation Products Group segment manufactures and sells products for the inland waterway and rail transportation industries including barges, barge-related products, axles, and couplers.

Closing Price
$43.95
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
331,816
0

Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020

11:01 am ET August 6, 2020 (BusinessWire) Print

Pfizer Inc. (NYSE: PFE) announced today that it will be holding its rescheduled Investor Day virtually over two days: Monday, September 14, 2020 from 1:00 p.m. EDT to approximately 4:00 p.m. EDT and Tuesday, September 15, 2020 from 10:00 a.m. EDT to approximately 1:00 p.m. EDT. Pfizer postponed its Investor Day, originally scheduled for March 31, 2020, due to health and safety concerns around the COVID-19 pandemic.

Information on registering for virtual attendance will be provided at a later date. A live webcast, including audio, video and presentation slides, will be accessible on www.pfizer.com/investors at the time of the meeting. Interested parties unable to watch the live webcast will be able to view and listen to an archived copy of the webcast, which will be available on www.pfizer.com/investors following the conclusion of the event.

About Pfizer: Breakthroughs That Change Patients' Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice: The webcast may include forward-looking statements about, among other things, our anticipated operating and financial performance, business plans and prospects, expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, revenue contribution, growth, performance, timing of exclusivity and potential benefits, strategic reviews, capital allocation objectives, plans for and prospects of our acquisitions and other business-development plans, benefits anticipated from the reorganization of our commercial operations in 2019, plans for and prospects of our acquisitions and other business development activities, including our proposed transaction with Mylan N.V. (Mylan) to combine Upjohn and Mylan to create a new global pharmaceutical company, Viatris, our acquisition of Array BioPharma Inc. and our transaction with GSK which combined our respective consumer healthcare businesses into a new consumer healthcare joint venture, our ability to successfully capitalize on growth opportunities or prospects, manufacturing and product supply, our efforts to respond to COVID-19, including our investigational vaccine candidate against SARS-CoV-2, our expectations regarding the impact of COVID-19 on our business, operations and financial results and plans relating to share repurchases and dividends, among other things, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

The forward-looking statements in the webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200806005721/en/

SOURCE: Pfizer Inc.

Media Relations: 
Amy Rose 
+1 (646) 592-3157 
Amy.Rose@Pfizer.com  

Investor Relations: 
Ryan Crowe 
+1 (212) 733-8160 
Ryan.Crowe@Pfizer.com
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.